NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

false stament after false stament

Not true, NWBO has partnerships with UCLA, Cambridge University, and multiple other research centers
WRONG Absurd to claim that researchers and scientists staffed and paid by third parties such as UCLA are actually and secretly NWBO employees. Why now not claim that all Merck employees are actually and secretly NWBO staff? Come on do it claim that lol. Your Kool-aid must have been extra spicy with some very forbidden ingredients. NWBO does NOT employ any scientists or researchers like a going concern biotech company would

Not true, https://stockanalysis.com/stocks/nwbo/statistics/ NWBO employees (22) as of Feb 2nd, 2024.
WRONG According to NWBO's OWN LinkedIn page, NWBO employs 16 staff which is a decrease of 4 people in a year.
https://www.linkedin.com/company/northwest-biotherapeutics/people/ But you would of course ignore that and refer to your own self-created page as a source laughable

Not true, LP is more than capable to lead NWBO.
WRONG Your claim that Linda Powers is a certified CFO https://edu.berkeleyme.com/course/certified-cfo/ is one of your other outright LIES. Twisting what I said are you know. I said "NWBO does not have a certified CFO needed to manage the hundreds of millions that large pharma is supposed to invest for the joint trials"

Not true, sales support is the last stage in the product development process.
WRONG. When clear in sight of drug approval, as with NWBO, the biotech that plans to sell the soon-to-be-approved drug, should start putting together a sales support team 1.5 years before drug appraisal. You have no idea what you are talking about. There is not a hint of any of that with NWBO. I can see you have no understanding of biotech drug development

Not true, the Flaskworks "EDEN" unit is the last of three phases of the Flaskworks product and has been extensively tested and no need for further development
Wrong. There are 4 milestones to be paid by NWBO to former Flaskworks. The first has been paid. Crickets on the rest, and as stock payouts they are a mandatory disclosure. At the 2022 ASM (where did that 2023 ASM go anyway?) LP said how they were testing various very different processes with Eden. That should be a clue that it could not just reproduce the existing process. And further they were to select a version to proceed forward on last year. Until we get a clear PR on this from NWBO not much or no progress has been made on Eden .

As I have said.
NWBO is not going concern. NWBO is a shell company only holding IP and patents, therefor there is only one conclusion here that can be made which is:
After DCVAXL has been UK-approved NWBO will be bought for what I think is around 20 billion USD